Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05575830
PHASE4

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

Sponsor: Calmy Alexandra

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of the adjuvanted recombinant Zoster vaccine (RZV, or Shingrix®) in older people (\> 50 years) living with HIV (PLWH) compared to age-matched healthy adults over a 1-year period.

Official title: Immune Response to the Recombinant Zoster Vaccine in People Living With HIV Over 50 Years of Age Compared to Non-HIV Age- and Gender-matched Controls - The Shingr'HIV Phase IV Multicenter Study

Key Details

Gender

All

Age Range

50 Years - 95 Years

Study Type

INTERVENTIONAL

Enrollment

225

Start Date

2022-12-14

Completion Date

2026-03-31

Last Updated

2025-09-05

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Recombinant Zoster Vaccine

Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60

Locations (10)

Hôpital Saint-André, CHU de Bordeaux

Bordeaux, Bordeaux, France

SMIT - Service de Maladies Infectieuses et Tropicales Le Tripode -Groupe Hospitalier Pellegrin

Bordeaux, France, France

CHU de Bordeaux - Hôpital Haut-Lévèque

Pessac, Gironde, France

University Hospital Basel

Basel, Basel, Switzerland

Bern University Hospital (Inselspital)

Bern, Canton of Bern, Switzerland

University Hospitals of Geneva

Geneva, Canton of Geneva, Switzerland

Kantonsspital

Sankt Gallen, Canton of St. Gallen, Switzerland

Centre Hospitalier Universitaire Vaudoise (CHUV)

Lausanne, Canton of Vaud, Switzerland

University Hospital Zurich

Zurich, Canton of Zurich, Switzerland

Ente Ospedaliero Cantonale

Lugano, Canton Ticino, Switzerland